Clinical trial · Interventional
Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors
A Phase I Trial of Subcutaneous And/Or Oral Calcitriol [(1,25-COH)2D3] and Carboplatin in Advanced Solid Tumors
NCT00008086CI-TRIAL-00013120completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Calcitriol may help solid tumor cells develop into normal cells. Combining calcitriol with chemotherapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of calcitriol combined with carboplatin in treating patients who have advanced solid tumors.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain and Central Nervous System Tumors | — | UNRESOLVED | — |
| Unspecified Adult Solid Tumor, Protocol Specific | Adult Solid Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| calcitriol | Dietary Supplement | — | UNRESOLVED |
| carboplatin | Drug | Carboplatin | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed advanced solid tumor that is not curable by standard therapy, including glioma and other brain tumors * Brain metastases allowed following definitive radiotherapy PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * ECOG 0-2 Life expectancy: * At least 8 weeks Hematopoietic: * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic: * Bilirubin no greater than 1.5 mg/dL * SGOT no greater than 4 times normal Renal: * Creatinine no greater than 1.5 mg/dL OR * Creatinine clearance at least 60 mL/min * Creatinine no greater than 2.0 mg/dL * Calcium no greater than 10.5 mg/dL Cardiovascular: * No unstable angina * No symptomatic coronary artery disease Other: * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use 2 forms of barrier contraception AND 1 form of hormonal contraception for at least 1 week before, during, and for at least 2 weeks after study * No active infection * No other concurrent serious condition PRIOR CONCURRENT THERAPY: Biologic therapy: * At least 4 weeks since prior biologic therapy (regional or systemic) Chemotherapy: * At least 4 weeks since prior chemotherapy Endocrine therapy: * No concurrent glucocorticoids as antiemetics * Concurrent exogenous glucocorticoids allowed for treatment of gliomas or other brain tumors Radiotherapy: * See Disease Characteristics * At least 4 weeks since prior radiotherapy Surgery: * Not specified Other: * Dietary calcium intake of no more than 200-250 mg/day beginning 48 hours before each course and continuing for 7 days * No concurrent dairy products, green leafy vegetables, molasses, baking powder, fortified cereals, and dry peas and beans
References
Publications (0)
Data not yet available
No reference posted for this study.